<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340898</url>
  </required_header>
  <id_info>
    <org_study_id>114858</org_study_id>
    <nct_id>NCT01340898</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK
      134612 in healthy infants, when co-administered with other infant vaccines, on three
      different dose schedules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol has been updated following Protocol Amendment 1 date 26 July 2011 leading to
      the update of enrollment, a secondary outcome measure, intervention and exclusion criteria
      sections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of number of subjects with a titer equal to or above the cut-off value</measure>
    <time_frame>One month post-dose 3 (Month 5)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of number of subject with titers equal to or above cut-off values</measure>
    <time_frame>One month post-dose 3 (Month 5), prior to (Month 13) and one month-post booster (Month 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the co-administered vaccines in terms of number of subjects with concentrations equal to or above cut-off values</measure>
    <time_frame>One month post-dose 3 (Month 5), prior to (Month 13) and one month-post booster (Month 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with solicited local and general symptoms</measure>
    <time_frame>Within 8 days (Day0 to Day7) after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with unsolicited adverse events</measure>
    <time_frame>Within 31 days (Day 0 to 30) after each vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events</measure>
    <time_frame>Throughout the study period (Month 0 to Month 19)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with new onset of chronic illnesses</measure>
    <time_frame>Throughout the study period (Month 0 to Month 19)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of antibody titers</measure>
    <time_frame>One month post-dose 3 (Month 5), prior to (Month 13) and one month-post booster (Month 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the investigational vaccine in terms of number of subjects with vaccine response</measure>
    <time_frame>At Month 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the co-administered vaccines in terms of antibody concentrations</measure>
    <time_frame>One month post-dose 3 (Month 5), prior to (Month 13) and one month-post booster (Month 14)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">753</enrollment>
  <condition>Meningococcal Infection</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who receive 3 primary doses and 1 booster dose of the investigational vaccine, (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who receive 1 primary dose and 1 booster dose of the investigational vaccine, (1 dose at 6 months of age followed by a booster dose at 15-18 months of age)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who receive 1 dose of the investigational vaccine, at 15-18 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal vaccine GSK 134612</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SynflorixTM</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix-IPV/HiberixTM</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that parent(s)/Legally Acceptable
             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.

          -  A male or female, 6 to 12 weeks (42-90 days) of age at the time of the first
             vaccination.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Born after a gestation period of at least 36 weeks.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Extended administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the period 30 days before and after each study vaccine administration, with the
             exception of rotavirus vaccine and seasonal or pandemic influenza vaccine.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Previous vaccination against diphtheria , tetanus, pertussis, polio (with the
             exception of a birth dose of OPV), Haemophilus influenzae type b, Streptococcus
             pneumonia.

          -  History of receipt of meningococcal vaccine.

          -  Subjects who received a birth dose Hepatitis B vaccines within the 30 days before the
             administration of the first study vaccine.

          -  History of or intercurrent diphtheria, tetanus, pertussis, polio, Haemophilus
             influenzae type b disease, pneumococcal and/or meningococcal disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of th
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107-2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
    <country>Mexico</country>
  </location_countries>
  <removed_countries>
    <country>Pakistan</country>
    <country>Saudi Arabia</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <disposition_first_submitted>March 12, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 12, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 1, 2015</disposition_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningococcal conjugate vaccine</keyword>
  <keyword>serogroups A,C, W-135 or Y</keyword>
  <keyword>meningococcal diseases</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>co-administration</keyword>
  <keyword>routine vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 11, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

